Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opexa Therapeutics, a company developing Tovaxin, a personalised T-cell therapy for multiple sclerosis (MS), has been issued two patents by the US Patent and Trademark Office, with a third patent expected to be issued later this month based on a received Notice of Allowance. These issued and allowed patents strengthen the Opexa patent estate related to its T-cell vaccine franchise.
Subscribe to our email newsletter
Opexa said that the newly issued patents are US patent nos 7,695,713 and 7,658,926, the granted claims of which are directed to its proprietary process for manufacturing its T-cell vaccines as well as to compositions of such vaccines having reactivity to critical MS antigens.
Additionally, a notice of allowance has also been received for Opexa’s US Patent Application serial no 10/520,296, which is directed to T-cell vaccines based on autoreactive T-cell receptor epitopes found in most of the MS patients.
Neil Warma, president and CEO of Opexa, said: “Strengthening our patent position in the area of T-cell technology has been a key objective for us over the past twelve months and is important for Opexa’s long term value.
“Our T-cell technology is the backbone of the Tovaxin development program which is in late clinical development for the treatment of MS. We view intellectual property protection as critical for maintaining and enhancing our long term competitive position.”